Patents by Inventor Rashi SRIVASTAVA

Rashi SRIVASTAVA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligodendrocyte progenitor cell compositions
    Patent number: 11920155
    Abstract: Compositions comprising a population of oligodendrocyte progenitor cells (OPCs), as well as methods of making and using the same, are provided. In one aspect, a container comprising a composition, where the composition comprises a population of cells comprising a plurality of OPCs, and where the population of cells comprises less than 15% undesirable cell types is provided. In another aspect, the population of cells comprises less than 15% undesirable epithelial lineage cells. In yet another aspect, the population of cells comprises less than 2% K7 positive cells. In an aspect, a population of cells comprising a plurality of oligodendrocyte progenitor cells is capable of forming less than one epithelial cyst per 100,000 cells in a cyst assay is provided. An even further aspect of the present disclosure is a container comprising a composition, where the composition comprising a plurality of oligodendrocyte progenitor cells is useful in treating treat stroke, spinal cord injury, and multiple sclerosis.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: March 5, 2024
    Assignee: ASTERIAS BIOTHERAPEUTICS, INC.
    Inventors: Erik Michael Whiteley, Uzma Shoukat-Mumtaz, Rashi Srivastava, Nathan Charles Manley, Casey Christopher Case
  • OLIGODENDROCYTE PROGENITOR CELL COMPOSITIONS
    Publication number: 20210189335
    Abstract: Compositions comprising a population of oligodendrocyte progenitor cells (OPCs), as well as methods of making and using the same, are provided. In one aspect, a container comprising a composition, where the composition comprises a population of cells comprising a plurality of OPCs, and where the population of cells comprises less than 15% undesirable cell types is provided. In another aspect, the population of cells comprises less than 15% undesirable epithelial lineage cells. In yet another aspect, the population of cells comprises less than 2% K7 positive cells. In an aspect, a population of cells comprising a plurality of oligodendrocyte progenitor cells is capable of forming less than one epithelial cyst per 100,000 cells in a cyst assay is provided. An even further aspect of the present disclosure is a container comprising a composition, where the composition comprising a plurality of oligodendrocyte progenitor cells is useful in treating treat stroke, spinal cord injury, and multiple sclerosis.
    Type: Application
    Filed: March 30, 2017
    Publication date: June 24, 2021
    Applicant: Asterias Biotherapeutics, Inc.
    Inventors: Erik Michael WHITELEY, Uzma SHOUKAT-MUMTAZ, Rashi SRIVASTAVA, Nathan Charles MANLEY, Casey Christopher CASE